ENGLEWOOD, Colo., Dec. 8,
2020 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE
American: AMPE), a biopharmaceutical company focused on the
advancement of immunology-based therapies for prevalent
inflammatory conditions, announced today that the Company will
conduct its annual meeting in a virtual format only on December 12, 2020 at 9:00
am MST. Additional details regarding the meeting are as
follows:
Annual Meeting Webcast Link and Call-in
Number:
Webcast link:
www.virtualshareholdermeeting.com/AMPE2020
U.S./Canada toll-free number:
1-877-328-2502
Please note that the call-in line and webcast link will be muted
for the duration of the meeting; however, shareholders will be able
to submit their votes and/or questions via the webcast as long as
they have their 16-digit control number, which was previously
provided on their proxy statement.
An audio replay of the annual meeting will be posted on the
Company's website within 24 hours of the meeting
(https://ampiopharma.com/investors/presentations-media).
Forward Looking Statements
Ampio's statements in this
press release that are not historical fact, and that relate to
future plans or events, are forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995, as amended to date. Forward-looking statements can be
identified by the use of words such as "believe," "expect," "plan,"
"anticipate," and similar expressions. These forward-looking
statements include statements regarding Ampio's expectations with
respect to the safety and efficacy of Ampion and its
classification, as well as those associated with regulatory
approvals and other FDA decisions, the Biologics License
Application (BLA), the ability of Ampio to enter into partnering or
licensing arrangements, current or future clinical trials, changes
in business conditions and similar events (including currently
unforeseen risks associated with COVID-19), the possibility that
Ampion may be used to treat ARDS induced by COVID-19, Ampio's
ability to continue as a going concern and its ability to continue
to raise funds using its "at-the-market" equity offering or
otherwise, all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, in Ampio's
Annual Report on Form 10-K for the period ended December 31, 2019, and in subsequent reports on
Forms 10-Q and 8-K and other filings made by Ampio with the
Securities and Exchange Commission. Accordingly, you should not
place undue reliance on these forward-looking statements. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
Media Relations
Sarah May
sarahm@gregoryfca.com
215-205-1217
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-host-its-annual-meeting-on-december-12-2020-301188429.html
SOURCE Ampio Pharmaceuticals, Inc.